➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Merck
McKesson
Harvard Business School
McKinsey

Last Updated: January 20, 2021

DrugPatentWatch Database Preview

CARMUSTINE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Carmustine, and when can generic versions of Carmustine launch?

Carmustine is a drug marketed by Amneal, Dr Reddys, Navinta Llc, and Sti Pharma Llc. and is included in four NDAs.

The generic ingredient in CARMUSTINE is carmustine. There are eleven drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the carmustine profile page.

US ANDA Litigation and Generic Entry Outlook for Carmustine

A generic version of CARMUSTINE was approved as carmustine by NAVINTA LLC on September 11th, 2018.

  Start Trial

Drug patent expirations by year for CARMUSTINE
Drug Prices for CARMUSTINE

See drug prices for CARMUSTINE

Recent Clinical Trials for CARMUSTINE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Verastem, Inc.Phase 2
General Oncology, Inc.Phase 2
Acerta Pharma BVPhase 2

See all CARMUSTINE clinical trials

Medical Subject Heading (MeSH) Categories for CARMUSTINE

US Patents and Regulatory Information for CARMUSTINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Amneal CARMUSTINE carmustine INJECTABLE;INJECTION 211229-001 Oct 16, 2018 AP RX No No   Start Trial   Start Trial   Start Trial
Sti Pharma Llc CARMUSTINE carmustine INJECTABLE;INJECTION 209278-001 Apr 2, 2019 AP RX No No   Start Trial   Start Trial   Start Trial
Dr Reddys CARMUSTINE carmustine INJECTABLE;INJECTION 213207-001 Oct 22, 2020 AP RX No No   Start Trial   Start Trial   Start Trial
Navinta Llc CARMUSTINE carmustine INJECTABLE;INJECTION 210179-001 Sep 11, 2018 AP RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Moodys
Dow
McKesson
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.